Clinical trials
Progressive Familial Intrahepatic Cholestasis clinical trials
Below are recruiting progressive familial intrahepatic cholestasis clinical trials, each written for real people, not researchers. We’re tracking 11 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06778174Recruiting
Treating progressive familial intrahepatic cholestasis
This study tracks treatments and outcomes for people with a confirmed genetic form of PFIC, a rare liver disease. It helps doctors learn which treatments work best for each type.
GroningenAges Any age - NCT06777914Recruiting
Genes linked to rare liver disease and cancer risk
This study looks at whether certain family-related genes make people more likely to develop liver or bile duct cancers without a clear cause. If you had surgery or a transplant for one of these cancers and have had unexplained high liver enzymes or itching, this trial may help find genetic clues.
Bologna, BolognaAges 1 year+ - NCT07185919Recruiting
Odevixibat (Bylvay) study for PFIC patients in South Korea
This study is tracking how well odevixibat (Bylvay) works and how safe it is for people with progressive familial intrahepatic cholestasis (PFIC) in South Korea. It is for patients who are already prescribed this medicine by their doctor, and it monitors their progress over time.
GyeongsangAges Any age - NCT03930810Enrolling by invitation
Study of PFIC types and how bile diversion affects outlook
This study looks at different genetic liver conditions called PFIC and follows how they progress over time. It also studies whether a procedure called biliary diversion may improve symptoms or long-term outcomes.
Groningen, Provincie GroningenAges birth–65 years - NCT07317193Recruiting
Genetic causes of adult bile duct disease
This study looks for new genes that might cause abnormal liver test results or specific bile duct diseases in adults, when standard testing hasn't found a clear cause. It also uses healthy blood donors as a comparison group.
Milan, MilanoAges 18–65 - NCT07588880Recruiting
Tracking Odevixibat Safety and Outcomes in PFIC Patients
This study follows patients with PFIC (a rare liver disease affecting bile flow) who are taking or planning to take odevixibat (Bylvay), a medication that helps manage the condition. Researchers will track how well the medication works, any side effects, and long-term health outcomes in Chinese patients.
BeijingAges 6 months+ - NCT06193928Recruiting
Long-term safety study of Livmarli in ALGS or PFIC
This study is following patients who are already taking Livmarli (maralixibat) for Alagille syndrome or PFIC to see how safe and effective it is over the long term.
Los Angeles, CaliforniaAges Any age - NCT06781242Recruiting
Genes and symptoms in inherited bile flow problems
This study looks at how genes affect bile flow problems in the liver. If you have a rare genetic condition like PFIC, researchers want to understand your specific type better by comparing your genes to your symptoms.
Bologna, BolognaAges 18 years+ - NCT07290257RecruitingPhase 4
Long-term safety study of Livmarli for Alagille syndrome or PFIC
This study looks at the long-term safety and effects of Livmarli (maralixibat) in children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC). It may help understand how well the medicine works over time for itching and other symptoms.
BrusselsAges 2 months+ - NCT07293897Recruiting
Study of Livmarli for Alagille Syndrome and PFIC
This study looks at how well Livmarli works for people with Alagille syndrome or a liver disease called PFIC. It uses data from prescriptions to understand the treatment's effects.
Tokyo, TokyoAges Any age - NCT07411716Recruiting
Children's liver disease registry in Canada
This study creates a registry to track children with specific genetic liver conditions that cause cholestasis (slow bile flow). Being in the registry helps researchers better understand these diseases and may help future patients.
Calgary, AlbertaAges Up to 18 years
Hear when a new Progressive Familial Intrahepatic Cholestasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progressive familial intrahepatic cholestasis?
- Yes. Clin2 currently lists 11 recruiting progressive familial intrahepatic cholestasis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progressive familial intrahepatic cholestasis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progressive familial intrahepatic cholestasis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.